honokiol has been researched along with Clinically Isolated CNS Demyelinating Syndrome in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gan, S; Gong, R; Ma, L; Mou, KJ; Sun, S; Tan, Y; Wu, J; Xu, S; Xue, J; Yu, H | 1 |
1 other study(ies) available for honokiol and Clinically Isolated CNS Demyelinating Syndrome
| Article | Year |
|---|---|
Honokiol exerts protective effects on neural myelin sheaths after compressed spinal cord injury by inhibiting oligodendrocyte apoptosis through regulation of ER-mitochondrial interactions.
Topics: Animals; Apoptosis; Biphenyl Compounds; Caspase 12; Caspase 3; Cytochromes c; Demyelinating Diseases; Endoplasmic Reticulum; Humans; Lignans; Mitochondria; Myelin Sheath; Rats; Rats, Sprague-Dawley; Spinal Cord; Spinal Cord Injuries | 2022 |